Department of Anaesthesia and Intensive Care, Nouvel Hôpital Civil Strasbourg (University Hospitals), Strasbourg Cedex, France.
J Thromb Haemost. 2010 Mar;8(3):499-503. doi: 10.1111/j.1538-7836.2009.03685.x. Epub 2009 Nov 12.
After a vitamin K antagonist (VKA) overdose, 1-2 mg of oral vitamin K can lower the International Normalized Ratio (INR) to the therapeutic range.
To establish whether oral vitamin K can substitute for heparin bridging and decrease the INR to < or = 1.5 before elective surgery.
Patients on long-term VKAs were randomized either to heparin bridging after the last VKA dose on day -5 before surgery (group H) or to VKA treatment until day -2, followed by 1 mg of oral vitamin K on the day before surgery (group K). Blood clotting variables were assessed on days -5/-2, 1 and 0, and postoperatively. If the target INR was not achieved 2 h before incision, surgery was deferred or performed after injection of prothrombin complex concentrate (PCC).
In 30 of 94 included patients, baseline INR was outside the chosen range (18, INR < 2; 12, INR > 3.5), leaving 34 eligible patients in group H and 30 in group K. The groups were balanced in terms of body mass index, VKA treatment duration and indication, scheduled surgery, preoperative and postoperative hemoglobin, and blood loss. The INR was significantly higher in group K on days -1 and 0 than in group H. An INR < or = 1.5 was not achieved in 20 group K patients (66%). Surgery was postponed or performed after PCC injection in 12 of these 20 patients.
Oral vitamin K (1 mg) cannot substitute for heparin bridging before surgery. In addition, one-third of patients on VKAs were exposed to a risk of bleeding (overdose) or thrombosis (underdose), thus highlighting the need for new oral anticoagulants.
维生素 K 拮抗剂(VKA)过量后,口服 1-2 毫克维生素 K 可将国际标准化比值(INR)降低至治疗范围。
确定口服维生素 K 是否可以替代肝素桥接,并在择期手术前将 INR 降低至<或=1.5。
长期服用 VKA 的患者随机分为肝素桥接组(手术前第 5 天最后一次 VKA 剂量后)(组 H)或 VKA 治疗组直至第 2 天,然后在手术前一天口服 1 毫克维生素 K(组 K)。在第-5/-2、1 和 0 天和术后评估凝血变量。如果目标 INR 在切口前 2 小时内未达到,则推迟手术或注射凝血酶原复合物浓缩物(PCC)后进行。
在 94 例纳入患者中,有 30 例患者的基线 INR 超出所选范围(18,INR<2;12,INR>3.5),组 H 中有 34 例患者符合条件,组 K 中有 30 例患者符合条件。两组在体重指数、VKA 治疗时间和适应证、计划手术、术前和术后血红蛋白和失血方面均平衡。组 K 的 INR 在-1 天和 0 天明显高于组 H。组 K 中有 20 例(66%)患者的 INR<或=1.5 未达到。在这些 20 名患者中,有 12 名患者推迟手术或在注射 PCC 后进行手术。
口服维生素 K(1 毫克)不能替代术前肝素桥接。此外,三分之一的 VKA 患者面临出血(过量)或血栓形成(剂量不足)的风险,这突出表明需要新的口服抗凝剂。